Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Exagen Inc. (XGN) Misses Q2 EPS by 21c; Lowers Outlook
August 4, 2022 4:50 PM EDTExagen Inc. (NASDAQ: XGN) reported Q2 EPS of ($0.78), $0.21 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $9 million versus the consensus estimate of $12.03 million.
GUIDANCE:
Exagen Inc. sees Q3 2022 revenue of $35-40 million, versus the consensus of... More
